Mark DeMario

2.1k total citations
25 papers, 809 citations indexed

About

Mark DeMario is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark DeMario has authored 25 papers receiving a total of 809 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark DeMario's work include Cancer Treatment and Pharmacology (7 papers), Protein Degradation and Inhibitors (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Mark DeMario is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Protein Degradation and Inhibitors (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Mark DeMario collaborates with scholars based in United States, Switzerland and Denmark. Mark DeMario's co-authors include Mark J. Ratain, Geoffrey I. Shapiro, Stanislaw M. Mikulski, Ka Wang, Darlene Gibbon, Wells A. Messersmith, Jonathan Deutsch, Gerald S. Falchook, James Song and Amita Patnaik and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Mark DeMario

25 papers receiving 798 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark DeMario United States	14	437	402	102	94	82	25	809
Nicoletta Staropoli Italy	14	233 0.5×	350 0.9×	112 1.1×	111 1.2×	74 0.9×	42	617
Carla Kurkjian United States	17	481 1.1×	302 0.8×	157 1.5×	130 1.4×	41 0.5×	41	830
Rob Pieters Netherlands	15	352 0.8×	342 0.9×	59 0.6×	113 1.2×	266 3.2×	27	957
Shane K. Green Canada	7	462 1.1×	378 0.9×	117 1.1×	233 2.5×	36 0.4×	9	795
Andrea Ghelli Luserna di Rorà Italy	13	513 1.2×	303 0.8×	64 0.6×	98 1.0×	115 1.4×	38	735
Renata Binato Brazil	19	532 1.2×	205 0.5×	68 0.7×	168 1.8×	109 1.3×	60	876
Alessandro Perez Italy	15	301 0.7×	272 0.7×	206 2.0×	181 1.9×	57 0.7×	41	693
Ralf Jesnowski Germany	18	554 1.3×	664 1.7×	71 0.7×	198 2.1×	44 0.5×	35	1.1k
Natalia Liem Singapore	14	566 1.3×	302 0.8×	97 1.0×	136 1.4×	168 2.0×	18	944
Benjamin D. Hedley Canada	16	464 1.1×	544 1.4×	104 1.0×	228 2.4×	190 2.3×	40	1.1k

Countries citing papers authored by Mark DeMario

Since Specialization

Citations

This map shows the geographic impact of Mark DeMario's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark DeMario with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark DeMario more than expected).

Fields of papers citing papers by Mark DeMario

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark DeMario. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark DeMario. The network helps show where Mark DeMario may publish in the future.

Co-authorship network of co-authors of Mark DeMario

This figure shows the co-authorship network connecting the top 25 collaborators of Mark DeMario. A scholar is included among the top collaborators of Mark DeMario based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark DeMario. Mark DeMario is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Borgers, Jessica S.W., Brian J. McCarthy, Victoria Kohler, et al.. (2023). 1017O NTC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma. Annals of Oncology. 34. S619–S619. 1 indexed citations

Dickinson, Michael, Javier Briones, Alex F. Herrera, et al.. (2021). Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood Advances. 5(22). 4762–4770. 29 indexed citations

Awad, Mark M., Ramaswamy Govindan, David R. Spigel, et al.. (2021). Abstract 73: A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first-line non-squamous NSCLC: Associations with clinical outcomes. Cancer Research. 81(13_Supplement). 73–73. 4 indexed citations

Lheureux, Stéphanie, Erika Hamilton, George Au‐Yeung, et al.. (2021). Abstract LB104: Dose-Finding/Expansion Phase Ib Study to Evaluate the Safety and Activity of BET Inhibitor RO6870810 (RO) and Atezolizumab (A) in Patients (pts) with Advanced Ovarian Cancer (OC) or Triple Negative Breast Cancer (TNBC). Cancer Research. 81(13_Supplement). LB104–LB104. 2 indexed citations

Roboz, Gail J., Pinkal Desai, Sangmin Lee, et al.. (2021). A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia & lymphoma. 62(7). 1740–1748. 31 indexed citations

Shapiro, Geoffrey I., Patricia LoRusso, Afshin Dowlati, et al.. (2020). A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. British Journal of Cancer. 124(4). 744–753. 83 indexed citations

Caimi, Paolo F., Joseph P. Eder, Eric D. Jacobsen, et al.. (2017). A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC‐EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). Hematological Oncology. 35(S2). 263–265. 3 indexed citations

Milletti, Francesca, Wei‐Yi Cheng, Tamara Maes, et al.. (2016). Abstract 4708: Neuroendocrine gene transcript expression is associated with efficacy to lysine-specific demethylase-1 inhibitor RG6016 in small cell lung cancer-derived cell lines. Cancer Research. 76(14_Supplement). 4708–4708. 15 indexed citations

Lassen, Ulrik, Didier Meulendijks, L.L. Siu, et al.. (2014). A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers. Clinical Cancer Research. 21(2). 258–266. 32 indexed citations

10.

Herold, Andrea, Tobias Bergauer, Anton Belousov, et al.. (2012). Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays. Methods. 59(1). 10–19. 14 indexed citations

11.

Lassen, Ulrik, Jan H.M. Schellens, L.L. Siu, et al.. (2012). 29 A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors. European Journal of Cancer. 48. 12–12. 4 indexed citations

12.

Tolcher, Anthony W., Wells A. Messersmith, Stanislaw M. Mikulski, et al.. (2012). Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors. Journal of Clinical Oncology. 30(19). 2348–2353. 207 indexed citations

13.

Tolcher, A. W., Stanislaw M. Mikulski, Wells A. Messersmith, et al.. (2010). A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2502–2502. 14 indexed citations

14.

Berkofsky‐Fessler, Windy, Paul Delmar, Juliette Molnos, et al.. (2009). Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. Molecular Cancer Therapeutics. 8(9). 2517–2525. 18 indexed citations

15.

Overmoyer, Beth, Stanley E. Waintraub, P. Kaufman, et al.. (2005). Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. Journal of Clinical Oncology. 23(16_suppl). 778–778. 17 indexed citations

16.

Desai, Apurva A., Federico Innocenti, Linda Janisch, et al.. (2004). A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 54(5). 377–384. 6 indexed citations

17.

Dupont, Jakob, Carol Aghajanian, S. Pezzulli, et al.. (2004). Phase I and Pharmacokinetic Study of the Novel Oral Cell-Cycle Inhibitor Ro 31-7453 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 22(16). 3366–3374. 12 indexed citations

18.

Salazar, Ramón, Donald Bissett, Chris Twelves, et al.. (2004). A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors. Clinical Cancer Research. 10(13). 4374–4382. 6 indexed citations

19.

DeMario, Mark, Mark J. Ratain, Nicholas J. Vogelzang, et al.. (1999). A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemotherapy and Pharmacology. 43(5). 385–388. 13 indexed citations

20.

DeMario, Mark & Mark J. Ratain. (1998). Oral chemotherapy: rationale and future directions.. Journal of Clinical Oncology. 16(7). 2557–2567. 240 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact